Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Thursday, March 7, 2013
CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
Approximately 6% to 10% of people with HIV are also infected with HBV, and coinfection is associated with more rapid liver disease progression than HBV monoinfection.